Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.

@article{Jojima2009GlimepirideUE,
  title={Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.},
  author={Teruo Jojima and Kenji Suzuki and Noriko Hirama and Kazuyo Uchida and Yuichi Hattori},
  journal={Diabetes, obesity & metabolism},
  year={2009},
  volume={11 2},
  pages={143-9}
}
AIMS Several studies suggest increased mortality postcoronary angioplasty in patients on sulphonylureas. However, a theoretical reduction in cardiac risk has been suggested with the newer sulphonylurea agents, which differ from the first-generation agents. In the present study, we investigated whether a third generation of sulphonylurea, glimepiride, might stimulate nitric oxide (NO) production and thereby inhibit cytokine-induced nuclear factor (NF)-kappaB activation in endothelial cells… CONTINUE READING
14 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Effects of treatment with sulfonylurea drugs or insulin on ischemia - induced myocardia dysfunction in type 2

  • CE Schotborgh, AA Wilde
  • DIABETES
  • 2002

Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardia dysfunction in type 2 diabetes

  • R Scognamiglio, A Avogaro, S Vigili de Kreutzenberg
  • Diabetes
  • 2002

Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride

  • S Shakuto, Y Sato, K Ohshima, M. Yaguchi
  • Diabet Complications 2001;
  • 2001

Similar Papers

Loading similar papers…